Special Issue "PI3K/PDK1/Akt Pathways in Cancer"
A special issue of Cancers (ISSN 2072-6694).
Deadline for manuscript submissions: closed (31 January 2017)
Prof. Dr. Marco Falasca
School of Pharmacy & Biomedical Sciences, Faculty of Health Science, Curtin University, Perth, Australia
Website | E-Mail
Interests: signal transduction; cancer invasion and metastasis; phosphoinositide signalling; PI3-kinase/PDK1 signalling pathway; ABC transporters; G protein-coupled receptors; exosomes
Phosphoinositide 3-kinases (PI3Ks) enzymes are important signalling molecules involved in a variety of different cellular functions. They use phosphoinositides as substrates and they exert their function through phosphorylation of the D3 position within the inositol ring, generating PtdIns3P, PtdIns(3,4)P2 and PtdIns(3,4,5)P3. The PI3K family contains eight mammalian isoforms grouped into three classes in accordance with substrate specificity and structure. Interestingly, there is a variety of genetic abnormalities observed in the PI3K pathway in cancer, such as activating and deactivating mutations and post-transcriptional epigenetic irregularities. It is a common phenomenon in solid tumours to witness aberrant PI3Kα activity, directly or indirectly resulting from mutations of the respective gene; therefore PI3Kα inhibition is an emerging approach for treating these types of tumours and indeed there are a number of relevant ongoing trials. Nevertheless, emerging evidence supports the role of other PI3K isoforms in cancer as well as the complexity and specificity of activation of PI3K downstream effectors. Indeed, novel signaling pathways and cell functions are continuously identified as regulated by PI3K isoforms in cancer. The combined data indicate that the biological functions of PI3K isoforms are far more complex than presently known and that the overall responses to PI3K-inhibiting drugs are likely to be context-dependent. This Special Issue will cover the recent progress in all areas related to PI3K signaling and cancer.
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Phosphoinositides 3-Kinases
- cell signalling
- drug resistance
- 3-phosphoinositide dependent protein kinase-1
- Protein kinase B/Akt